Du Plessis D J, Celliers D, Van Rensburg A J, Lindeque K P
S Afr Med J. 1982 Jul 28;62(5 Spec No):8A-11A.
Augmentin, a formulation of amoxycillin trihydrate 250 mg and sodium clavulanate 125 mg per tablet (A-CS) (Augmentin; Beecham), was used in treating 29 episodes of urinary tract infection occurring in 26 patients admitted to the Spinal Unit of the H. F. Verwoerd Hospital, Pretoria. Patients who had a urinary bacterial cell count of more than 105 of the same amoxycillin-resistant organism before and after the oral administration of amoxycillin 500 mg 3 times a day for 48 hours, received 2 A-CS 375 mg tablets orally, 3 times a day at the start if a meal for 5 days. The 29 strains of amoxycillin-resistant organisms treated in this study were: Escherichia coli (11), Klebsiella pneumoniae (11), Proteus mirabilis (4), Enterobacter cloacae (2), and Staphylococcus epidermidis (1). The bacteriological success rate 24 hours after therapy was 100% and 8 days after therapy 69%, dependent on patient management. In patients on free drainage and managed with condoms a bacteriological success rate of 55,5% was recorded and in patients managed by intermittent catheterization a bacteriological success rate of 75% was recorded. Side-effects were minimal; 1 patient complained of dizziness and no instances of nausea or vomiting were reported. Haematological, renal and hepatic monitoring before and after A-CS-therapy revealed no drug-related toxicity.
奥格门汀，每片含三水阿莫西林250毫克和克拉维酸钠125毫克的制剂（A-CS）（奥格门汀；必治妥施贵宝公司），用于治疗比勒陀利亚H.F.韦沃尔德医院脊髓科收治的26例患者发生的29次尿路感染。在每日3次口服500毫克阿莫西林共48小时前后，尿液中同一种耐阿莫西林菌的细菌细胞计数均超过105的患者，开始时在饭前口服2片375毫克的A-CS，每日3次，共5天。本研究中治疗的29株耐阿莫西林菌为：大肠杆菌（11株）、肺炎克雷伯菌（11株）、奇异变形杆菌（4株）、阴沟肠杆菌（2株）和表皮葡萄球菌（1株）。治疗后24小时细菌学成功率为100%，治疗后8天为69%，这取决于患者的管理情况。在采用自由引流并用避孕套管理的患者中，细菌学成功率为55.5%，在采用间歇性导尿管理的患者中，细菌学成功率为75%。副作用极小；1例患者抱怨头晕，未报告有恶心或呕吐情况。在A-CS治疗前后进行的血液学、肾脏和肝脏监测未发现与药物相关的毒性。
